David G. Sherman讲座:改善卒中诊断与治疗——走向终结的旅程
2024年David G. Sherman讲座中,Steven J. Warach结合自身研究,回顾了1990年代至2000年代初磁共振成像在急性卒中中的应用历史,包括弥散加权成像、缺血半暗带成像等的引入、验证及进入常规临床实践和卒中试验的过程。文章指出,基于直接观察靶向病理而非仅依赖临床和时间替代指标来选择急性卒中治疗患者,这一转变在过去10年扩大了急性再灌注治疗的适应证。
要点
- 弥散加权成像使缺血性病灶在卒中发作后最早时间即可可视化,而CT和常规MRI仍表现正常。
- 弥散-灌注成像使缺血半暗带成像成为常规临床实用工具,并可作为临床试验选择工具。
- 许多患者卒中发作后24小时仍存在半暗带,但半暗带概率随时间下降。
核心结论
- 基于直接观察靶向病理而非仅依赖临床和时间替代指标来选择急性卒中治疗患者,这一转变在过去10年扩大了急性再灌注治疗的适应证。
研究设计与样本
- 2024年David G. Sherman讲座,Steven J. Warach以自身研究为例,回顾磁共振成像在急性卒中中的历史与应用。
主要发现
- 弥散加权成像在卒中发作后最早时间即可显示缺血病灶的存在、位置和大小,而CT和常规MRI仍表现正常。
- 弥散-灌注成像使缺血半暗带成像成为常规临床实用工具,并可作为临床试验的选择工具。
- 许多患者卒中发作后24小时仍存在半暗带,但半暗带概率随时间下降。
- 基于临床和时间标准选择的治疗时间窗反映了治疗靶点患者比例随时间下降,而非所有患者晚期均无半暗带靶点。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the 2024 David G. Sherman Lecture, Steven J. Warach, illustrating with examples from his research, walks through the history of magnetic resonance imaging in acute stroke from the 1990s and early 2000s with the introduction, validation, and application of diffusion-weighted imaging, penumbral imaging (the diffusion-perfusion mismatch), and other imaging markers of the acute stroke pathology into routine clinical practice and stroke trials. The adaptation of diffusion-weighted imaging for clinical scanners in the acute hospital setting began a revolution in ischemic stroke diagnosis as the presence, location, and size of ischemic lesions could now be visualized at the earliest times after stroke onset when computed tomography and conventional magnetic resonance imaging still appeared normal. In combination with perfusion magnetic resonance imaging, diffusion-weighted imaging made imaging of the ischemic penumbra a practical reality for routine clinical use and feasible for integration as a selection tool into clinical trials. It was apparent from the initial use of diffusion-perfusion imaging in acute stroke that many patients had persistence of penumbra as late as 24 hours after stroke onset although the probability of penumbra decreased over time. The therapeutic time window for ischemic stroke selected by clinical and temporal criteria reflected the decreased proportion of patients with the therapeutic target over time rather than the absence of the penumbral target in all patients at later times. This work provided the empirical and conceptual framework for the shift toward selection and evaluation of patients for acute stroke therapies based on direct observation of the target pathology and away from the exclusive dependence on clinical and temporal surrogates to infer the presence of stroke therapeutic targets, a shift that has expanded the indications for acute reperfusion therapies over the last 10 years.
引用
- Warach SJ. David G. Sherman Lecture: Improving Stroke Diagnosis and Treatment-A Journey Toward the End of Time. Stroke. 2024. PMID: 39315824. doi:10.1161/STROKEAHA.124.046919
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。